Radioligand therapy uses radio-labeled antibodies to deliver targeted radiation directly to prostate cancer cells, minimizing ...

Pluvicto (lutetium-177 vipivotide tetraxetan) is a radioligand therapy that targets the PSMA protein on prostate cancer cells ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply to new ...

(ST. JOSEPH, Mo) Mosaic Life Care is advancing its cancer treatment for patients with metastatic prostate cancer. PLUVICTO is ...

Canadian leadership in medical isotope innovation is saving lives across our great country and around the world. This ...

Pluvicto is approved in the U.S., the E.U. and other countries to treat adults with a type of advanced cancer called PSMA-positive mCRPC and who have already been treated with other anticancer ...

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...

Pluvicto is supplied as a 30mL single-dose vial containing 1000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan. The product is expected to be available in the coming weeks.

New report finds colorectal cancer rising among U.S. adults under 55 Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week.

Novartis to Make Pluvicto Radioligand Therapy at Indianapolis Plant Production boost to meet growing demand from cancer patients in North America By Mauro Orru Jan. 5, 2024 3:33 pm ET ...

Shortage of Last-Ditch Drug for Advanced Prostate Cancer Worries Doctors Novartis seeks to ramp up Pluvicto production to ease supply issues By Jennifer Calfas and Melanie Evans March 16, 2023 5: ...